You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • O21 Is SLE-DAS better than BILAG-2004 to identify severe SLE disease activity? Post-hoc analysis of 438 SLE patients from the anifrolumab clinical trials

Article info

Article menu

Download PDFPDF

Oral Presentations
O21 Is SLE-DAS better than BILAG-2004 to identify severe SLE disease activity? Post-hoc analysis of 438 SLE patients from the anifrolumab clinical trials

Authors

  • Diogo Jesus Rheumatology Dept., Centro Hospitalar de Leiria, Leiria, Portugal Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal PubMed articlesGoogle scholar articles
  • Carla Henriques School of Technology and Management, Polytechnic Institute of Viseu, Viseu, Portugal Centre for Mathematics, University of Coimbra, Coimbra, Portugal PubMed articlesGoogle scholar articles
  • Ana Matos School of Technology and Management, Polytechnic Institute of Viseu, Viseu, Portugal Research Centre in Digital Services (CISeD), Viseu, Portugal PubMed articlesGoogle scholar articles
  • Andrea Doria Reumatology Unit, Dept. of Medicine, University of Padova, Padova, Italy PubMed articlesGoogle scholar articles
  • Luís Sousa Inês Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal CHUC Lupus Clinic, Rheumatology Dept., Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal PubMed articlesGoogle scholar articles

Citation

Jesus D, Henriques C, Matos A, et al
O21 Is SLE-DAS better than BILAG-2004 to identify severe SLE disease activity? Post-hoc analysis of 438 SLE patients from the anifrolumab clinical trials
Lupus Science & Medicine 2024;11:doi: 10.1136/lupus-2024-el.31

Publication history

  • First published March 14, 2024.
Online issue publication 
March 15, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ .